Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 4
Submit an article Journal homepage
2,326
Views
27
CrossRef citations to date
0
Altmetric
Original Research

Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors

Chang-Long ChenDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China;Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Qiu-Zhong PanDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China;Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
De-Sheng WengDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China;Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Chuan-Miao XieDepartment of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Jing-Jing ZhaoDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China;Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Min-Shan ChenCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China;Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Rui-Qing PengDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. ChinaView further author information
,
Dan-Dan LiDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. ChinaView further author information
,
Ying WangDepartment of Immunization Program, Haizhu District Center for Disease Control and Prevention, Guangzhou, ChinaView further author information
,
Yan TangDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China;Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Qi-Jing WangDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. ChinaView further author information
,
Zhi-Ling ZhangDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Xiao-Fei ZhangDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China;Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Li-Juan JiangDepartment of Urology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Zi-Qi ZhouDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China;Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Qian ZhuDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China;Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Jia HeDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. ChinaView further author information
,
Yuan LiuDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China;Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Fang-Jian ZhouCollaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China;Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
&
Jian-Chuan XiaDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China;Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, ChinaCorrespondence[email protected]
View further author information
 show all
Article: e1417721 | Received 20 Oct 2017, Accepted 07 Dec 2017, Published online: 10 Jan 2018

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Maryam Abbaspour & Vajihe Akbari. (2022) Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence. Expert Review of Vaccines 21:3, pages 337-353.
Read now
Huiru Xu, Weishan Qin, Huijing Feng, Dong Song, Xiaoling Yang & Junping Zhang. (2021) Analysis of the Clinical Efficacy of Dendritic Cell –cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer. Immunological Investigations 50:6, pages 622-633.
Read now
Shuo Wang, Xiaoli Wang, Xinna Zhou, Herbert Kim Lyerly, Michael A. Morse & Jun Ren. (2020) DC-CIK as a widely applicable cancer immunotherapy. Expert Opinion on Biological Therapy 20:6, pages 601-607.
Read now
Jenny Sprooten, Jolien Ceusters, An Coosemans, Patrizia Agostinis, Steven De Vleeschouwer, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Abhishek D. Garg. (2019) Trial watch: dendritic cell vaccination for cancer immunotherapy. OncoImmunology 8:11.
Read now
Ewelina Grywalska, Marcin Pasiarski, Stanisław Góźdź & Jacek Roliński. (2018) Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. OncoTargets and Therapy 11, pages 6505-6524.
Read now

Articles from other publishers (22)

Liwei Liu & Bo Liu. (2023) Inflammatory microenvironment and immunotherapy in hepatocellular carcinoma. European Journal of Inflammation 21, pages 1721727X2311720.
Crossref
Rohulla Vaseq, Amit Sharma, Yutao Li & Ingo G. H. Schmidt-Wolf. (2023) Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors. International Journal of Molecular Sciences 24:6, pages 5626.
Crossref
Shaochuan Liu, Yuan Meng, Liang Liu, Yingge Lv, Feng Wei, Wenwen Yu, Limei Wang, Xiying Zhang, Xiubao Ren & Qian Sun. (2022) Rational pemetrexed combined with CIK therapy plus anti-PD-1 mAbs administration sequence will effectively promote the efficacy of CIK therapy in non-small cell lung cancer. Cancer Gene Therapy 30:2, pages 277-287.
Crossref
Geetha Shanmugam, Sumana Das, Sambuddha Paul, Sudeshna Rakshit & Koustav Sarkar. (2022) Clinical relevance and therapeutic aspects of professional antigen-presenting cells in lung cancer. Medical Oncology 39:12.
Crossref
Jiage Ding, Yanyan Zheng, Gang Wang, Junnian Zheng & Dafei Chai. (2022) The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:5, pages 188763.
Crossref
Ying Zhang, Xiaolong Wu, Amit Sharma, Hans Weiher, Matthias Schmid, Glen Kristiansen & Ingo G. H. Schmidt-Wolf. (2022) Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma. Frontiers in Immunology 13.
Crossref
Liang Zhou, Qijiu Chen, Hui Chen, Li Wang & Jianyong Zhang. (2022) Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-11.
Crossref
Ji Son, Goldy C. George, Mirella Nardo, Kate J. Krause, Amir A. Jazaeri, Amadeo B. Biter & David S. Hong. (2022) Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. Gynecologic Oncology 165:3, pages 664-670.
Crossref
Ilenia Iaia, Loretta Gammaitoni, Giulia Cattaneo, Lidia Giraudo, Chiara Donini, Erika Fiorino, Luca Primo, Fabrizio Carnevale-Schianca, Massimo Aglietta, Alberto Puliafito & Dario Sangiolo. (2021) Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models. Cancers 13:10, pages 2302.
Crossref
Dieter Stevens, Joline Ingels, Sandra Van Lint, Bart Vandekerckhove & Karim Vermaelen. (2021) Dendritic Cell-Based Immunotherapy in Lung Cancer. Frontiers in Immunology 11.
Crossref
Xin Yuan, An Zhi Zhang, Yi Lin Ren, Xue Li Wang, Chen Hao Jiang, Lan Yang, Chun Xia Liu, Wei Hua Liang, Li Juan Pang, Wen Yi Gu, Feng Li & Jian Ming Hu. (2021) Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer. Medicine 100:13, pages e24519.
Crossref
Meng‐Jia Song, Qiu‐Zhong Pan, Ya Ding, Jianxiong Zeng, Pei Dong, Jing‐Jing Zhao, Yan Tang, Jingjing Li, Zhiling Zhang, Junyi He, Jieying Yang, Yue Huang, Ruiqing Peng, Qi‐Jing Wang, Jia‐Mei Gu, Jia He, Yong‐Qiang Li, Shi‐Ping Chen, Rongxing Huang, Zi‐Qi Zhou, Chaopin Yang, Yulong Han, Hao Chen, Heping Liu, Shangzhou Xia, Yang Wan, De‐Sheng Weng, Liming Xia, Fang‐Jian Zhou & Jian‐Chuan Xia. (2021) The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study. Clinical & Translational Immunology 10:3.
Crossref
Chao Wang, Ming Li, Rong Wei & Junlong Wu. (2020) Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. Journal of Bone Oncology 25, pages 100332.
Crossref
Ying Zhang & Ingo G. H. Schmidt‐Wolf. (2020) Ten‐year update of the international registry on cytokine‐induced killer cells in cancer immunotherapy. Journal of Cellular Physiology 235:12, pages 9291-9303.
Crossref
Ying Zhang, Jörg Ellinger, Manuel Ritter & Ingo G. H. Schmidt-Wolf. (2020) Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma. Cancers 12:9, pages 2471.
Crossref
Shan Zhu, Ning Yang, Jing Wu, Xue Wang, Wan Wang, Yong-Jun Liu & Jingtao Chen. (2020) Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy. Pharmacological Research 159, pages 104980.
Crossref
Jing Shi, Ming Li & Rongzhi Yang. (2020) Tumor-infiltrating lymphocytes as a feasible adjuvant immunotherapy for osteosarcoma with a poor response to neoadjuvant chemotherapy. Immunotherapy 12:9, pages 641-652.
Crossref
Yue Shi, Xiaoping Men, Xueting Li, Zhicun Yang & Hongjuan Wen. (2020) Research progress and clinical prospect of immunocytotherapy for the treatment of hepatocellular carcinoma. International Immunopharmacology 82, pages 106351.
Crossref
蓁臻 陈. (2020) Research Progress of Adoptive Cellular Immunotherapy for the Treatment of Hepatocellular Carcinoma. Advances in Clinical Medicine 10:11, pages 2710-2715.
Crossref
Jing-Bo Wang, Xue Huang & Fu-Rong Li. (2019) Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives. Cancer Communications 39:1, pages 43.
Crossref
Lijun Liang, Yixuan Wen, Rong Hu, Lei Wang, Youyou Xia, Chenxi Hu, Yun Qiao, Xiaowei Geng, Ting Chen, Jiayan Fei, Kaiyuan Hui & Xiaodong Jiang. (2019) Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials. Cancer Immunology, Immunotherapy 68:9, pages 1467-1477.
Crossref
Lingdi Zhao, Tiepeng Li, Yonghao Yang, Yong Zhang, Wei Li, Lu Han, Yiman Shang, Hongwei Lin, Xiubao Ren & Quanli Gao. (2019) Clinical value of neutrophil-to-lymphocyte ratio as a predictor of prognosis of RetroNectin ® -activated cytokine-induced killer cell therapy in advanced non-small-cell lung cancer . Immunotherapy 11:4, pages 273-282.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.